Phase 1, randomised, food effect, PK study of GWP42003-P capsules

  • Research type

    Research Study

  • Full title

    A Phase 1, Randomised, 2 part Trial to Investigate the Effect of Food on Cannabidiol (GWP42003-P, CBD) Capsule versus Oral Solution Pharmacokinetics (PK) and to Assess the Single and Repeat Dose PK, in Healthy Subjects

  • IRAS ID

    248660

  • Contact name

    Firas Almazedi

  • Contact email

    Firas.Almazedi@covance.com

  • Sponsor organisation

    GW Research Ltd

  • Eudract number

    2018-002027-42

  • Clinicaltrials.gov Identifier

    18/NE/0197, REC Reference number

  • Duration of Study in the UK

    0 years, 3 months, 22 days

  • Research summary

    GWP42003-P is the substance for purified cannabidiol (CBD) from the cannabis plant being developed by GW pharma, CBD is not associated with the effects cannabis is traditionally known for and is being investigated for the treatment of a number of conditions, namely some treatment resistant childhood epilepsies like Dravet syndrome and Lennox-Gastaut syndrome, central nervous system disorders and inflammatory disorders. \n\nThis study is being carried out to investigate how food affects the way the drug is used by the body, they will be testing two versions of the drug, one is a capsule and the other is an oral solution. They will also be testing how the drug is used by the body with repeated doses of the capsule formulation of the drug. \nThe study will take part in 2 parts\n\nThe first part will be investigating the effect of food on the solution and the capsules of the study drug in a fed and fasted state. There will be four treatment sequences for 12 subjects, which will be randomly allocated to each subject. There will be a 2 week period before each dosing period. \n\nThe second part of the study will consist of 3 groups of 12 subjects; they will be given three different oral doses of the study drug in its capsulated form (450mg, 750mg and 1500mg) the order in which these will be given will differ for each subject. After each dose they will wait for 3 weeks before receiving the next dose. \n

  • REC name

    North East - York Research Ethics Committee

  • REC reference

    18/NE/0197

  • Date of REC Opinion

    18 Jul 2018

  • REC opinion

    Further Information Favourable Opinion